Moderna stock falls 4.99 percent after a 52-week high
Published on 09/30/2026 at 12:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Moderna Inc. (ISIN US60770K1079) was trading at EUR 169.57 at Lang & Schwarz on September 30, 2026, at 12:08 p.m. CEST, down 4.99 percent from the prior close of EUR 178.48. The market is weighing the biotechnology company’s oncology pipeline against a still substantial earnings loss.
Melanoma data set next
On September 21, Moderna said Phase 3 data for intismeran autogene in resected stage IIB-IV melanoma had been selected for a Presidential Symposium at the European Society for Medical Oncology Congress.
The company also scheduled an investor webcast for October 24, 2026, at 7:00 p.m. CEST, or 1:00 p.m. EDT. That date gives the stock a defined clinical checkpoint after its recent move to a 52-week high of USD 202.69 on September 29.
Revenue beats consensus
For Q2 2026, Moderna reported revenue of USD 145.0 million, a GAAP net loss of USD 782.0 million and diluted GAAP EPS of USD -1.97, according to Moderna in its July 31 release.
MarketBeat reported that revenue exceeded the USD 102.93 million consensus by 40.88 percent, while the USD 1.97 per-share loss was USD 0.06 better than the USD 2.03 estimate. Moderna reiterated a plan for up to 10.00 percent revenue growth in 2026.
Analyst targets stay lower
MarketBeat counted four sell ratings, 13 hold ratings and seven buy ratings on September 25, producing a consensus Hold view across 24 research firms. The average 12-month target was USD 76.72 against a reported share price of USD 194.82, a gap that keeps valuation central to the debate.
Euro quote turns lower
At Lang & Schwarz, Moderna stock was trading at EUR 169.57 on September 30, 2026, at 12:08 p.m. CEST, down 4.99 percent versus the prior close of EUR 178.48. The Nasdaq quote was last at USD 203.46 on September 29, 2026, with a 52-week range of USD 22.28 to USD 208.90 and market capitalization of USD 80.7 billion.
Moderna stock key data
- Company: Moderna, Inc.
- ISIN: US60770K1079
- Ticker: MRNA
- Primary exchange: NASDAQ
- Price Lang & Schwarz (as of September 30, 2026, 12:08 p.m. CEST): EUR 169.57
- Change versus prior close: minus 4.99 percent
- Prior close Lang & Schwarz (September 29, 2026): EUR 178.48
- Market capitalization: USD 80.7 billion (as of September 29, 2026)
- 52-week range: USD 22.28-208.90 (as of September 29, 2026)
- Sector / Industry: Healthcare / Biotechnology
